Art. -Nr.: HY-N0217

Benzoylaconine

(Synonyms: Benzoylaconitine; Isaconitine; Pikraconitin)

1 Cited Publications

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Benzoylaconine (Benzoylaconitine) is an orally active monoester alkaloid found in the traditional Chinese medicine Aconitum carmichaelii. Benzoylaconine is an ACE2 agonist (EC₅₀: 1.5 μM) with antihypertensive and anti-heart failure effects. Benzoylaconine inhibits TLR-induced MAPK and NF-κB pathways to exert anti-inflammatory effects. Benzoylaconine upregulates the protein levels of P-gp, MRP2, and has anti-tumor effects.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 99.92%
CAS. Nr.: 466-24-0
Formel: C₃₂H₄₅NO₁₀
Molecular Weight:603.70

Speicherung:

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Benzoylaconine Chemical Structure

CAS. Nr.: 466-24-0

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Publications (1)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

ACE

0.32 μM (EC₅₀)

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen :

Alle NF-κB Isoform-spezifische Produkte anzeigen :

Alle COX Isoform-spezifische Produkte anzeigen :

Alle NO Synthase Isoform-spezifische Produkte anzeigen :

Alle p38 MAPK Isoform-spezifische Produkte anzeigen :

In Vitro

Benzoylaconine (25-100 μM, pretreatment for 1 h, then 36 h) has the effect of reducing angiotensin II-induced cardiomyocyte hypertrophy and fibrosis in cardiomyocytes and cardiac fibroblasts^[1].
Benzoylaconine (50 μM, pretreatment for 1 h, then 0.5, 36 h) cannot alleviate myocardial inflammation and injury by targeting ACE2 in ACE2 knockdown cardiomyocytes^[1].
Benzoylaconine (1-100 μM, 1 h) exerts anti-inflammatory effects in RAW264.7 macrophages by inhibiting TLR-induced MAPK and NF-κB pathways^[2].
Benzoylaconine (1-100 μM, pretreatment for 1 h, then 24 h) significantly reduces the levels of IL-1β, TNF-α, and IL-6 cytokine proinflammatory cytokines in LPS-induced RAW264.7 macrophages^[2].
Benzoylaconine (1-100 μM, pretreatment for 1 h, then 24 h) dose-dependently reduces the expression of COX-2 and iNOS in LPS-induced RAW264.7 macrophages^[2].
Benzoylaconine (27-75 μM, 2 days) dose-dependently promotes mitochondrial mass and thus mitochondrial biogenesis in HepG2 cells^[3].
Benzoylaconine has an agonistic effect on ACE2 activity (EC₅₀: 1.5 μM) and a significant inhibitory effect on ACE (EC₅₀: 0.32 μM)^[5].
Benzoylaconine (25-100 μM, 6 days) upregulates the protein levels of P-glycoprotein (P-gp), multidrug resistance-associated protein 2 (MRP2), and breast cancer resistance protein (BCRP) in Caco-2 and LS174T cells^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[1]

Cell Line:

cardiomyocytes and cardiac fibroblasts
Concentration:

50 μM
Incubation Time:

Pretreatment for 1 h and then exposure to Ang Ⅱ (HY-13948) (1 μM) for 36 h
Result:

Inhibited p38/ERK phosphorylation, reduced Drp1 mitochondrial translocation, and decreased ROS and NF-κB nuclear translocation.
Significantly inhibited the expression of β-MyHC and TGF-β proteins in rat primary cardiomyocytes and COL1A1, TGF-β primary cardiac fibroblasts induced by Ang Ⅱ in a dose-dependent manner.

Western Blot Analysis^[2]

Cell Line:

RAW264.7 cells
Concentration:

1-100 μM
Incubation Time:

Pretreatment for 1 h and then exposure to LPS (1 μg/mL) for 24 h
Result:

Inhibited PGE2 and NO release by downregulating COX-2 and iNOS levels.
Decreased p-p38/p38, p-JNK/JNK and p-ERK/ERK by affecting the MAPK pathway.
Significantly dose-dependently attenuated IκBα phosphorylation and degradation in activated macrophages.

Parmacokinetics

Species	Dose	Route	T_max	Plasma Concentration	T_1/2
Rat^[7]	1 mg/kg	p.o.	0.31 h	3.99 ng/mL	9.49 h

In Vivo

Benzoylaconine (3-30 mg/kg, p.o., 4 weeks) effectively improves cardiac dysfunction, reduces cardiomyocyte hypertrophy and cardiac tissue fibrosis in the thoracic aortic constriction (TAC) mouse model by targeting ACE2^[1].
Benzoylaconine (10 mg/kg, i.p., once a day for seven consecutive days) increases the oxygen consumption of mice, induces mitochondrial biogenesis and activated the AMPK-PGC1ɑ pathway in mice, exerting an anti-heart failure effect^[3].
Benzoylaconine (20 mg/kg, i.v. or i.g., once a day for five consecutive days) significantly inhibits the swelling of the mouse ear and sole in the mouse ear swelling test (MEST) and the mouse foot swelling test, indicating that it has an anti-inflammatory effect^[4].
Benzoylaconine (3-30 mg/kg, p.o., once a day for 14 consecutive days) can reduce heart rate and vasodilation in the SHR mouse model, and exert antihypertensive effects by reversing smooth muscle remodeling^[5].
Benzoylaconine (0.6 mg/kg, p.o., once a day for 14 consecutive days) significantly induces the expression and efflux activity of MRP2, BCRP, and P-gp in the jejunum, ileum, and colon of FVB mice in the FVB mouse model^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL/6 mice (male aged 8 weeks) TAC-induced model^[1]
Dosage:

3, 10, 30 mg/kg
Administration:

p.o., 4 weeks
Result:

Dose-dependently improved ejection fraction (EF%), fractional shortening (FS%), and decreased end-systolic volume (ESV) in TAC mice.
Reduced myocardial cell cross-sectional area, decreased cardiac collagen deposition, decreased circulating levels of BNP, LDH, and Ang Ⅱ, and increased levels of Ang (1-7).
Completely eliminated the improvement effects on cardiac function, hypertrophy and fibrosis in ACE knockout mice, indicating that it acted through ACE2.

Animal Model:

Kunming mice (female 20 g)^[4]
Dosage:

20 mg/kg
Administration:

i.v. (MEST) or i.g. (MPST), once a day for five consecutive days
Result:

Showed that the swelling inhibition rate in the MEST model reached 50%. In the MPST model, the inhibition rate increased significantly with time, reaching the highest inhibition rate (78.4%) at 6 hours.

Animal Model:

Spontaneous hypertensive rats (male 280 g)^[5]
Dosage:

3, 10, 30 mg/kg
Administration:

p.o. once a day for fourteen consecutive days
Result:

Indicated that it can not only inhibit the activity and protein expression of ACE, but also activate ACE2 activity in a dose-dependent manner.
Increased NO levels in SHR in a dose-dependent manner, reduced serum TNF-α and IL-6 levels, and downregulated COX-2 expression and IKB - α phosphorylation.
Showed targeting ACE/ACE2 to regulate vasodilation and vascular inflammation.
Decreased ACE and Ang Ⅱ levels and significantly increased Ang (1–7) levels, but did not change Ang Ⅰ and ACE2 levels.

Animal Model:

Friend leukemia virus mice (male 20-22 g)^[6]
Dosage:

0.6 mg/kg
Administration:

p.o. once a day for fourteen consecutive days
Result:

Significantly increased the levels of MRP2 and BCRP protein and mRNA in the jejunum, ileum and colon of mice.
Upregulated protein levels in mice and promotes nuclear translocation of Nrf2 in cells.

Chemical Information

CAS. Nr. 466-24-0
Appearance Solid
Molecular Weight 603.70
Formel C₃₂H₄₅NO₁₀
Color White to light yellow
SMILES

CO[C@@H]1C(C(N(CC)C2)C3[C@@H]4OC)([C@@](C[C@@]5(O)[C@@H]6OC(C7=CC=CC=C7)=O)([H])[C@@]6([H])[C@@]3([C@@H](O)[C@@H]5OC)O)[C@@]4([H])[C@@]2(COC)[C@H](O)C1
Synonyms

Benzoylaconitine; Isaconitine; Pikraconitin
Structure Classification
- Alkaloids
- Other Alkaloids
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture and light

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)

Publications (1)

All

Sort by:

Journal Impact Factor

Research Square Preprint

2021 Feb.

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 55 mg/mL (91.10 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6565 mL

8.2823 mL

16.5645 mL

5 mM

0.3313 mL

1.6565 mL

3.3129 mL

10 mM

0.1656 mL

0.8282 mL

1.6565 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 0.92 mg/mL (1.52 mM); Clear solution

This protocol yields a clear solution of ≥ 0.92 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (9.2 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 0.92 mg/mL (1.52 mM); Clear solution

This protocol yields a clear solution of ≥ 0.92 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (9.2 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 0.92 mg/mL (1.52 mM); Clear solution

This protocol yields a clear solution of ≥ 0.92 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (9.2 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (298 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Zhang QQ, et.al. Benzoylaconitine: A promising ACE2-targeted agonist for enhancing cardiac function in heart failure. Free Radic Biol Med. 2024 Mar;214:206-218. [Content Brief]

[2]. Zhou C, et al. Benzoylaconine Modulates LPS-Induced Responses Through Inhibition of Toll-Like Receptor-Mediated NF-κB and MAPK Signaling in RAW264.7 Cells. Inflammation. 2021 Oct;44(5):2018-2032. [Content Brief]

[3]. Deng XH, et al. Benzoylaconine induces mitochondrial biogenesis in mice via activating AMPK signaling cascade. Acta Pharmacol Sin. 2019 May;40(5):658-665. [Content Brief]

[4]. Gai W, et al. Delivery of benzoylaconitine using biodegradable nanoparticles to suppress inflammation via regulating NF-κB signaling. Colloids Surf B Biointerfaces. 2020 Jul;191:110980. [Content Brief]

[5]. Zhang QQ, et al. A Novel Modulator of the Renin-Angiotensin System, Benzoylaconitine, Attenuates Hypertension by Targeting ACE/ACE2 in Enhancing Vasodilation and Alleviating Vascular Inflammation. Front Pharmacol. 2022 Mar 11;13:841435. [Content Brief]

[6]. Wu JJ, et al. Aconitum alkaloids, the major components of Aconitum species, affect expression of multidrug resistance-associated protein 2 and breast cancer resistance protein by activating the Nrf2-mediated signalling pathway. Phytomedicine. 2018 May 15;44:87-97. [Content Brief]

[7]. Zhang H, et al. Biological activities and pharmacokinetics of aconitine, benzoylaconine, and aconine after oral administration in rats. Drug Test Anal. 2016 Aug;8(8):839-46. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.6565 mL	8.2823 mL	16.5645 mL	41.4113 mL
	5 mM	0.3313 mL	1.6565 mL	3.3129 mL	8.2823 mL
	10 mM	0.1656 mL	0.8282 mL	1.6565 mL	4.1411 mL
	15 mM	0.1104 mL	0.5522 mL	1.1043 mL	2.7608 mL
	20 mM	0.0828 mL	0.4141 mL	0.8282 mL	2.0706 mL
	25 mM	0.0663 mL	0.3313 mL	0.6626 mL	1.6565 mL
	30 mM	0.0552 mL	0.2761 mL	0.5522 mL	1.3804 mL
	40 mM	0.0414 mL	0.2071 mL	0.4141 mL	1.0353 mL
	50 mM	0.0331 mL	0.1656 mL	0.3313 mL	0.8282 mL
	60 mM	0.0276 mL	0.1380 mL	0.2761 mL	0.6902 mL
	80 mM	0.0207 mL	0.1035 mL	0.2071 mL	0.5176 mL

Benzoylaconine

1 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Benzoylaconine

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

Membrane Transporter/Ion Channel Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Reprogramming Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Neuroprotective Compound Library

Alkaloids Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Antihypertensive Compound Library

Metabolic Enzyme Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Tibetan Medicine Compound Library

Heat-Clearing and Detoxification Traditional Chinese Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Ancient Chinese Classical Formulas Traditional Chinese Medicine Active Compound Library

Anti-Rheumatic Arthritis Compound Library

Diarrhea-Related Traditional Chinese Medicine Active Compound Library

Pattern Recognition Receptors Library

Mongolian Medicine Compound Library

Natural Product Diversity Scaffold Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Benzoylaconine

Alle Toll-like Receptor (TLR) Isoform-spezifische Produkte anzeigen

Alle NF-κB Isoform-spezifische Produkte anzeigen

Alle COX Isoform-spezifische Produkte anzeigen

Alle NO Synthase Isoform-spezifische Produkte anzeigen